Cysteine Modifiers Suggest an Allosteric Inhibitory Site on the CAL PDZ Domain
Overview
Authors
Affiliations
Protein-protein interactions have become attractive targets for both experimental and therapeutic interventions. The PSD-95/Dlg1/ZO-1 (PDZ) domain is found in a large family of eukaryotic scaffold proteins that plays important roles in intracellular trafficking and localization of many target proteins. Here, we seek inhibitors of the PDZ protein that facilitates post-endocytic degradation of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR): the CFTR-associated ligand (CAL). We develop and validate biochemical screens and identify methyl-3,4-dephostatin (MD) and its analog ethyl-3,4-dephostatin (ED) as CAL PDZ inhibitors. Depending on conditions, MD can bind either covalently or non-covalently. Crystallographic and NMR data confirm that MD attacks a pocket at a site distinct from the canonical peptide-binding groove, and suggests an allosteric connection between target residue Cys and the conserved Leu in the GLGI motif. MD and ED thus appear to represent the first examples of small-molecule allosteric regulation of PDZ:peptide affinity. Their mechanism of action may exploit the known conformational plasticity of the PDZ domains and suggests that allosteric modulation may represent a strategy for targeting of this family of protein-protein binding modules.
Cell type-specific regulation of CFTR trafficking-on the verge of progress.
Farinha C, Santos L, Ferreira J Front Cell Dev Biol. 2024; 12:1338892.
PMID: 38505263 PMC: 10949533. DOI: 10.3389/fcell.2024.1338892.
Sheehan C, Hampton T, Madden D J Biol Chem. 2022; 298(12):102552.
PMID: 36183834 PMC: 9723946. DOI: 10.1016/j.jbc.2022.102552.
Seisel Q, Lakumpa I, Josse E, Vives E, Varilh J, Taulan-Cadars M Pharmaceutics. 2022; 14(4).
PMID: 35456644 PMC: 9032934. DOI: 10.3390/pharmaceutics14040808.
Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.
Brusa I, Sondo E, Falchi F, Pedemonte N, Roberti M, Cavalli A J Med Chem. 2022; 65(7):5212-5243.
PMID: 35377645 PMC: 9014417. DOI: 10.1021/acs.jmedchem.1c01897.
Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.
Dougherty P, Wellmerling J, Koley A, Lukowski J, Hummon A, Cormet-Boyaka E J Med Chem. 2020; 63(24):15773-15784.
PMID: 33314931 PMC: 8011814. DOI: 10.1021/acs.jmedchem.0c01528.